Major life sciences roundtable debate reveals growth in regulatory outsourcing
Growth due to increasing complexity around affiliates’ roles.
A major industry debate by a Who’s Who of the life sciences industry has revealed growing interest in outsourcing of regulatory affairs (RA) activities due to the increased complexity in the role of international affiliate organisations. The debate’s findings, which have been distilled into a summary paper published by outsourcing and consulting services specialist ProductLife Group (PLG), will be aired via an exclusive webinar on 12 April.
The PLG Evolve roundtable debate, Brave New World: Outsourcing and the Changing Role of the Affiliate, brings together senior representatives from Merck, LEO Pharma, AbbVie, Sanofi and Lundbeck. During this seminal session, they debate the conflicting needs of local sales operations and corporate RA teams, and the role of specialist external services in helping to bridge these differences.
The panelists discuss variants in affiliate operating models, and explore how an outsourced approach to managing local regulatory activities, as well as safety documentation and managing safety case reports, can help overcome current challenges, enabling in-country affiliates to focus on building the business unfettered by administrative bureaucracy, while ensuring the quality, consistency and transparency needed at a corporate level to achieve compliance.
In the words of panellist Jesper Kihl, Vice President for Global Regulatory Affairs at LEO Pharma: “The environment in which we operate has become far more complex, margins are being squeezed, and room for manoeuvre is shrinking. Affiliates need to focus on commercial activities, so outsourcing regulatory, pharmacovigilance, and other activities, makes sense.”
The PLG Evolve virtual discussion covers concerns about and first-hand experiences of outsourcing affiliate RA and pharmacovigilance documentation activities, including the learning curve involved when shifting from internally managed processes to the outsourcing of affiliate administrative activities.
Related News
-
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News CPHI Barcelona Annual Report illuminates industry trends for 2024
The CPHI Annual Survey comes into it’s 7th year to report on the predicted trends for 2024. Over 250 pharma executives were asked 35 questions, with their answers informing the industry landscape for the next year, spanning all major pharma marke... -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Detecting Alzheimer's disease with a simple lateral flow test
A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance